John Ragard
Patrimonio netto: 37 591 $ in data 31/08/2026
Patrimonio netto: 37 591 $ in data 31/08/2026
John Ragard formerly worked at Aspira Women's Health, Inc., as Director from 2024 to 2025 and Friess Associates LLC, as Research Team Leader from 1993 to 2014.
Mr. Ragard received his undergraduate degree from The Wharton School of the University of Pennsylvania.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 04/06/2025 | 134.734 ( 0,29% ) | 37 591 $ | 31/08/2026 |
| Società | Posizione | Fine |
|---|---|---|
| ASPIRA WOMEN'S HEALTH INC. | Direttore/Membro del Consiglio | 04/06/2025 |
Friess Associates LLC
Friess Associates LLC Investment ManagersFinance Friess Associates is a discretionary investment manager that specializes in domestic (US) growth equity strategies. The firm offers growth equity strategies across the market capitalization spectrum ranging from micro to large. Accordingly, clients may choose a focused market capitalization strategy within that range or an all-capitalization strategy. They employ a research-driven investment process, and primarily utilize fundamental analysis for the selection of equity investments. Friess Associates will sell a stock when its research determines: (1) a company has deteriorating fundamentals such as contracting margins or reduced revenue growth, (2) investor expectations have become unrealistically high, (3) when it reaches Friess Associates’ internal target price, and (4) identifies a better investment idea. | Gestore di Portafoglio-Azioni | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 3 |
|---|---|
Friess Associates LLC
Friess Associates LLC Investment ManagersFinance Friess Associates is a discretionary investment manager that specializes in domestic (US) growth equity strategies. The firm offers growth equity strategies across the market capitalization spectrum ranging from micro to large. Accordingly, clients may choose a focused market capitalization strategy within that range or an all-capitalization strategy. They employ a research-driven investment process, and primarily utilize fundamental analysis for the selection of equity investments. Friess Associates will sell a stock when its research determines: (1) a company has deteriorating fundamentals such as contracting margins or reduced revenue growth, (2) investor expectations have become unrealistically high, (3) when it reaches Friess Associates’ internal target price, and (4) identifies a better investment idea. | Finance |
Aspira Women's Health, Inc.
Aspira Women's Health, Inc. BiotechnologyHealth Technology Develops and manufactures diagnostic test kits | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale